# A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer

> **NCT03356158** · PHASE1 · UNKNOWN · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 21 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** CPGJ602
- **BIOLOGICAL:** Cetuximab

## Key facts

- **NCT ID:** NCT03356158
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-15
- **Primary completion:** 2018-10-30
- **Final completion:** 2018-11-30
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2018-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03356158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03356158, "A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03356158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*